Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

The initial report of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2016-03, Vol.127 (12), p.1551-1558
Hauptverfasser:	Luskin, Marlise R., Lee, Ju-Whei, Fernandez, Hugo F., Abdel-Wahab, Omar, Bennett, John M., Ketterling, Rhett P., Lazarus, Hillard M., Levine, Ross L., Litzow, Mark R., Paietta, Elisabeth M., Patel, Jay P., Racevskis, Janis, Rowe, Jacob M., Tallman, Martin S., Sun, Zhuoxin, Luger, Selina M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - therapeutic use Clinical Trials and Observations Cytogenetics Daunorubicin - administration & dosage Daunorubicin - therapeutic use DNA (Cytosine-5-)-Methyltransferases - genetics Female fms-Like Tyrosine Kinase 3 - genetics Humans Induction Chemotherapy - methods Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Male Middle Aged Mutation Nuclear Proteins - genetics Prognosis Survival Analysis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The initial report of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed that induction therapy with high-dose (HD) daunorubicin (90 mg/m2) improved overall survival in adults
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood-2015-07-657403